Redeye provides an initial comment on Scandinavian ChemoTech’s Q4 2025 report. Sales came in below expectations, while costs were broadly in line with our estimates. We view the slower sales as a bump in the road rather than a change in the underlying growth trajectory, with a 30% growth rate still representing solid momentum. The company continues to expand its sales while maintaining disciplined cost control, supporting the long-term investment case.
LÄS MER
